Silva Pharmaceuticals Limited

সিলভা ফার্মাসিউটিক্যালস্ লিমিটেড

Ref: SPL/SD/2026/73
Date: October 28, 2026

1. **The Chairman**
   Bangladesh Securities and Exchange Commission (BSEC),
   Dhaka-1207.

2. **Managing Director**
   Dhaka Stock Exchange PLC (DSE),
   Dhaka-1229

3. **Managing Director**
   Chittagong Stock Exchange PLC (CSE),
   Chittagong

Subject: Board of Directors Meeting regarding Price Sensitive Information for Annual Financial Statements for the year ended 30th June, 2026 of Silva Pharmaceuticals Limited.

Dear Sir,
We are pleased to inform you that the Board of Directors Meeting of Silva Pharmaceuticals Limited held on Wednesday, 28th October, 2026 during 3.00 P.M. at its Corporate Office: House No. # 65, Road No. # 8/A, Dhanmondi, Dhaka-1209 and approved the Annual Financial Statements of the Company for the year ended 30th June, 2026 and took the following decisions in respect of holding 25th Annual General Meeting (AGM):

1. Recommended Dividend : **0.10% cash dividend for general shareholders, including ICB, excluding others sponsors/directors.** The sponsors and directors excluding ICB holds **34,198,500** shares and the general shareholders including ICB holds **102,301,500** shares. The total dividend amount of **bdt.1,023,015** will be required disbursed to the general shareholders including ICB.

2. Date and Time of AGM : **Tuesday, December 29, 2026 at 11:30 A.M.**

3. Venue of AGM : **Hybrid System(Both physical & Digital Platform)**

4. Record Date : **Tuesday, December 01, 2026**

The comparative key financial disclosures as per audited financial statements:

SL.NO.	Particulars	30-June-2026	30-June-2025
A.	Net Asset Value (NAV)	Tk.1,950,342,462	Tk. 2,113,040,947
B.	Net Asset Value Per Share(NAVPS)*	Tk.14.29	Tk.15.48
		01-July-2025 to 30-June-2026	01-July-2024 to 30-June-2025
C.	Net Profit after tax	Tk.(162,698,485)	Tk. (132,951,398)
D.	Earnings per Share (EPS) *	Tk.(1.19)	Tk. (0.97)
E.	Net Operating Cash Flow per Share (NOCFPS)	Tk.0.14	Tk. 0.10

* **Reason for Increase/decrease in the Financial Results**: The decline in net profit after tax and the resulting increase in net loss compared to the previous year were primarily driven by a reduction in sales volume, largely attributable to significant turnover within the field sales force. In addition, disruptions in electricity supply, supply chain challenges, and broader global and macroeconomic instability adversely affected the Company's overall business performance. The decline in Earnings per Share (EPS) was mainly attributable to the reduction in revenue and the increase in operating expenses. Consequently, the net loss incurred during the financial year resulted in a corresponding decline in Net Asset Value per Share (NAVPS). The improvement in Net Operating Cash Flow per Share (NOCFPS) was mainly attributable to more efficient collection of receivables and a strategic reduction in short-term payments to suppliers.

This is for your kind information and record.
Thanking you.
Sincerely,

Md. Iqbal Hossain
Company Secretary

Corporate & Registered Office:
House # 65, Road # 8/A (New)
Dhanmondi, Dhaka-1209, Bangladesh
Phone : +880-2-55000692, 8191336
Fax : +880-2-55000693
Email : info@silvapharma.com
Web : www.silvapharma.com

Factory:
Main Road, Maijdee Court
Noakhali, Bangladesh
Phone: +880-321-63301
Fax: +880-321-63303
Email: factory@silvapharma.com